BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 33035473)

  • 41. Estimating the direct effect of human papillomavirus vaccination on the lifetime risk of screen-detected cervical precancer.
    Inturrisi F; Lissenberg-Witte BI; Veldhuijzen NJ; Bogaards JA; Ronco G; Meijer CJLM; Berkhof J
    Int J Cancer; 2021 Jan; 148(2):320-328. PubMed ID: 32663316
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening.
    Schiffman M; Kinney WK; Cheung LC; Gage JC; Fetterman B; Poitras NE; Lorey TS; Wentzensen N; Befano B; Schussler J; Katki HA; Castle PE
    J Natl Cancer Inst; 2018 May; 110(5):501-508. PubMed ID: 29145648
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Five-Year Cervical (Pre)Cancer Risk of Women Screened by HPV and Cytology Testing.
    Uijterwaal MH; Polman NJ; Van Kemenade FJ; Van Den Haselkamp S; Witte BI; Rijkaart D; Berkhof J; Snijders PJ; Meijer CJ
    Cancer Prev Res (Phila); 2015 Jun; 8(6):502-8. PubMed ID: 25776933
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less.
    Katki HA; Gage JC; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S69-77. PubMed ID: 23519308
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The impact of age and high-risk human papillomavirus (hrHPV) status on the prevalence of high-grade cervical intraepithelial neoplasia (CIN2+) in women with persistent hrHPV-positive, cytology-negative screening samples: a prospective cohort study.
    Tidy JA; Lyon R; Ellis K; Macdonald M; Palmer JE
    BJOG; 2020 Sep; 127(10):1260-1267. PubMed ID: 32279427
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica,
    Bratti MC; Rodríguez AC; Schiffman M; Hildesheim A; Morales J; Alfaro M; Guillén D; Hutchinson M; Sherman ME; Eklund C; Schussler J; Buckland J; Morera LA; Cárdenas F; Barrantes M; Pérez E; Cox TJ; Burk RD; Herrero R
    Rev Panam Salud Publica; 2004 Feb; 15(2):75-89. PubMed ID: 15030652
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer: An Observational Cohort Study.
    Castle PE; Kinney WK; Xue X; Cheung LC; Gage JC; Zhao FH; Fetterman B; Poitras NE; Lorey TS; Wentzensen N; Katki HA; Schiffman M
    Ann Intern Med; 2018 Jan; 168(1):20-29. PubMed ID: 29181509
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.
    Gage JC; Schiffman M; Katki HA; Castle PE; Fetterman B; Wentzensen N; Poitras NE; Lorey T; Cheung LC; Kinney WK
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25038467
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Improving Risk Informed HPV Screening (IRIS) Study: Design and Baseline Characteristics.
    Gage JC; Raine-Bennett T; Schiffman M; Clarke MA; Cheung LC; Poitras NE; Varnado NE; Katki HA; Castle PE; Befano B; Chandra M; Rydzak G; Lorey T; Wentzensen N
    Cancer Epidemiol Biomarkers Prev; 2022 Feb; 31(2):486-492. PubMed ID: 34789470
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland.
    Leinonen MK; Nieminen P; Lönnberg S; Malila N; Hakama M; Pokhrel A; Laurila P; Tarkkanen J; Anttila A
    BMJ; 2012 Nov; 345():e7789. PubMed ID: 23197596
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cervical Precancer Risk in HIV-Infected Women Who Test Positive for Oncogenic Human Papillomavirus Despite a Normal Pap Test.
    Keller MJ; Burk RD; Massad LS; Eltoum IE; Hessol NA; Castle PE; Anastos K; Xie X; Minkoff H; Xue X; D'Souza G; Flowers L; Levine AM; Colie C; Rahangdale L; Fischl MA; Palefsky JM; Strickler HD
    Clin Infect Dis; 2015 Nov; 61(10):1573-81. PubMed ID: 26187020
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cervical Precancer and Cancer Risk by Human Papillomavirus Status and Cytologic Interpretation: Implications for Risk-Based Management.
    Castle PE; Aslam S; Behrens C
    Cancer Epidemiol Biomarkers Prev; 2016 Dec; 25(12):1595-1599. PubMed ID: 27587789
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.
    Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N
    Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk of cervical precancer among HPV-negative women in the Netherlands and its association with previous HPV and cytology results: A follow-up analysis of a randomized screening study.
    Inturrisi F; Rozendaal L; Veldhuijzen NJ; Heideman DAM; Meijer CJLM; Berkhof J
    PLoS Med; 2022 Oct; 19(10):e1004115. PubMed ID: 36306283
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reflex Human Papillomavirus Test Results as an Option for the Management of Korean Women With Atypical Squamous Cells Cannot Exclude High-Grade Squamous Intraepithelial Lesion.
    Ryu KJ; Lee S; Min KJ; Kim JW; Hong JH; Song JY; Lee JK; Lee NW
    Oncologist; 2015 Jun; 20(6):635-9. PubMed ID: 25964305
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of portable colposcopy and human papillomavirus testing for screening of cervical cancer in rural China.
    Newman H; Hu J; Li X; He J; Bradford L; Shan S; Wu X; Zhu B; Yang W; Fu B; Zhu B; Gao G
    Int J Gynecol Cancer; 2019 Jan; 29(1):23-27. PubMed ID: 30640679
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society.
    Fontham ETH; Wolf AMD; Church TR; Etzioni R; Flowers CR; Herzig A; Guerra CE; Oeffinger KC; Shih YT; Walter LC; Kim JJ; Andrews KS; DeSantis CE; Fedewa SA; Manassaram-Baptiste D; Saslow D; Wender RC; Smith RA
    CA Cancer J Clin; 2020 Sep; 70(5):321-346. PubMed ID: 32729638
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study.
    Castle PE; Rodríguez AC; Burk RD; Herrero R; Wacholder S; Alfaro M; Morales J; Guillen D; Sherman ME; Solomon D; Schiffman M;
    BMJ; 2009 Jul; 339():b2569. PubMed ID: 19638649
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cervical Colposcopy: Indications and Risk Assessment.
    Burness JV; Schroeder JM; Warren JB
    Am Fam Physician; 2020 Jul; 102(1):39-48. PubMed ID: 32603071
    [TBL] [Abstract][Full Text] [Related]  

  • 60. National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study.
    Smith MA; Sherrah M; Sultana F; Castle PE; Arbyn M; Gertig D; Caruana M; Wrede CD; Saville M; Canfell K
    BMJ; 2022 Mar; 376():e068582. PubMed ID: 35354610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.